

Multisystem Inflammatory Syndrome in Children

Tennessee Provider Update

MIS-C

- Multisystem inflammatory syndrome (MIS) is a rare but serious condition associated with COVID-19 in which different body parts become inflamed
 - MIS-C case definition includes people who are <21 years old

MIS-C Incidence

- MIS-C occurs in about 0.03% of SARS-CoV-2 infections (1 case of MIS-C per 3,200 SARS-CoV-2 infections in persons <21 years)
- Higher among Black, Hispanic/Latino, Asian/Pacific Islander and younger persons

MIS-C Mortality

- Mortality: 1.2% (95% CI: 0.1%-1.7%)
- Case fatality ratio decreased over time (<6/29/20: 2.4%, 6/29/20-11/6/20: 1.6%, 11/7/20-3/17/21: 0.7%)
- Highest number and likelihood of death among persons 16-20 years

https://www.cdc.gov/mis/about.html

Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Netw Open. 2021;4(6):e2116420. doi:10.1001/jamanetworkopen.2021.16420 Bowen A, Miller AD, Zambrano LD, et al. Demographic and Clinical Factors Associated With Death Among Persons <21 Years Old With Multisystem Inflammatory Syndrome in Children—United States, February 2020–March 2021. Open Forum Infectious Diseases. 2021;8(8). doi:10.1093/ofid/ofab388



MIS-C Symptoms

Children and adults with MIS experience:

- Ongoing fever PLUS more than one of the following:
 - Stomach pain
 - Bloodshot eyes
 - Diarrhea
 - Dizziness or lightheadedness (signs of low blood pressure)
 - Skin rash
 - Vomiting

How to Recognize

Multisystem Inflammatory Syndrome in Children (MIS-C)

A Delayed Immune Response Related to COVID-19

Children, adolescents, or young adults who develop certain symptoms after having COVID-19 might have MIS-C. They should see a doctor if they had COVID-19, or have been in close contact with someone who had COVID-19, within the past 6 weeks and now have the following:





PLUS more than one of the following:



Stomach Pain



Diarrhe



Vomitin



Blood Shot

>

Dizziness or Lightheadedness

Go to the nearest hospital Emergency Room if your child is showing any severe MIS-C warning signs such as:

Eyes

Trouble breathing | Pain or pressure in the chest that does not go away

Confusion or unusual behavior | Severe abdominal pain | Inability to wake or stay awake

Pale, gray, or blue-colored skin, lips, or nail beds; depending on skin tone









Reported MIS-C Cases by Jurisdiction

Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States

Last updated with cases reported to CDC on or before August 27, 2021*

TOTAL MIS-C PATIENTS MEETING CASE DEFINITION*

4,661


TOTAL MIS-C DEATHS MEETING CASE DEFINITION

41

MIS-C Cases by Jurisdiction

Since reporting began in 2020, 52 U.S. jurisdictions (including 49 states, New York City, Puerto Rico, and Washington, DC) have reported at least one MIS-C case to CDC. Because of the small number of patients reported in some jurisdictions, this report includes case ranges instead of exact case counts from individual jurisdictions to protect the privacy of patients and their families.







^{*}Additional patients are under investigation. After review of additional clinical data, patients may be excluded if there are alternative diagnoses that explained their illness.


MIS-C in Tennessee

Multi-System Inflammatory Syndrome in Children (MIS-C)

NBS Data Updated*: October 5, 2021

Confirmed Cases: 196 Probable Cases: 4 Under Investigation: 31

Confirmed and Probable Case Demographics Age **Case Ethnicity** Case Sex **Case Race** Hispanic/Latino 26 13% Black or African American 61 31% Min Age (Years): 0 90 Not Hispanic/Latino 83% White 108 165 Max Age (Years): 18 Null/Unknown 5% Other/Multiracial 31 Avg Age (Years):



^{*}Data suppressed due to small numbers (<10)
Cases with missing or unknown county of residence are not included in map.

Confirmed and Probable Case Outcomes

Hosp Length of Stay	
Min Hsptl Duration (Days)	0.0
Max Hsptl Duration (Days)	38.0
Avg Hsptl Duration (Days)	5.5

ICU Indicator		
	#	%
Yes	90	45%
No	110	55%

ICU Length of Stay	
Min ICU Duration (Days)	1.0
Max ICU Duration (Days)	31.0
Avg ICU Duration (Days)	3.8

Death Indicator				
	#	%		
Yes	1	1%		
No	199	100%		




110

MIS-C in Tennessee

Systems Involved in MIS-C Cases (Confirmed and Probable)

(limiting to cases with at least 1 system reported)






 $\frac{https://www.tn.gov/content/dam/tn/health/documents/cedep/novel-coronavirus/datasets/Multi-System-Inflammatory-Syndrome-In-Children.pdf$

MIS-C and COVID-19 Cases


Daily MIS-C Cases and COVID-19 Cases Reported to CDC (7-Day Moving Average)






Pediatric COVID-19 Cases in Tennessee

The week of 8/22/2021 (6 weeks ago), there was a peak of 21,939 confirmed pediatric COVID-19 cases





MIS-C in Tennessee





Reporting Criteria

Patients less than 21 years of age presenting with:

- **Fever:** at least 100.4°F for more than 24 hours, or report of subjective fever lasting more than 24 hours
- Inflammation: Laboratory evidence of inflammation including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), interleukin 6 (IL-6), or neutrophil count, or reduced lymphocyte count or low albumin
- Multisystem organ involvement: Evidence of clinically severe illness requiring hospitalization with multisystem organ involvement (cardiac, renal, respiratory, hematological, gastrointestinal, dermatologic or neurological)

AND

No evidence of alternative plausible diagnoses

Notes:

- Patients should be reported regardless of SARS-CoV-2 lab results
- Patients should be reported even if they meet full or partial criteria for Kawasaki disease
- Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection



TDH Reporting

- Healthcare providers who have cared or are caring for patients meeting MIS-C criteria are to report suspect cases to Amanda Hartley or Tina Herring at the Tennessee Department of Health within 24 hours of identification
- Contact information

Phone: 615-741-7247

Email: <u>VPD.IMM@tn.gov</u>

- Fax: 615-401-7709

What to send

- Patient demographic sheet
- H&P
- ID note, if available
- Lab evidence of elevated inflammatory markers



Acknowledgements

- Amanda Hartley
- Lizzie Harvey
- Tina Herring
- Erin Hodson
- Morgan McDonald
- Jessica Schultz
- EP Response



Questions? Tobi.Amosun@tn.gov
